The control of acute cisplatin-induced emesis - a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone
1993

Granisetron vs. Metoclopramide for Preventing Nausea from Cisplatin

Sample size: 281 publication Evidence: moderate

Author Information

Author(s): B. Chevallier, The Granisetron Study Group

Primary Institution: Centre Henri Becquerel, Rouen Cedex, France

Hypothesis

Is granisetron as effective as a combination of high-dose metoclopramide and dexamethasone in preventing cisplatin-induced nausea and vomiting?

Conclusion

Granisetron is as effective as the combination regimen for preventing nausea and vomiting caused by cisplatin, with fewer side effects.

Supporting Evidence

  • 70% of patients treated with granisetron were complete responders, compared to 67% in the comparator group.
  • Granisetron had a lower incidence of extrapyramidal reactions compared to the comparator group.
  • Headache was the most common side effect in the granisetron group, occurring in 9.8% of patients.

Takeaway

This study found that a single dose of granisetron can help stop patients from feeling sick after chemotherapy, just like a more complicated treatment that takes longer to give.

Methodology

A single-blind, multicentre study comparing granisetron with a combination of high-dose metoclopramide and dexamethasone in patients receiving cisplatin chemotherapy.

Potential Biases

Potential bias due to the single-blind design and the subjective nature of patient-reported outcomes.

Limitations

The study was single-blind, which may introduce bias, and it only included patients receiving cisplatin for the first time.

Participant Demographics

{"total_patients":281,"male":183,"female":98,"mean_age":56.6,"race":{"caucasian":272,"other":9}}

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication